Epidemiologic study of aripiprazole use and the incidence of suicide events
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Because second generation antipsychotics (SGA) might affect the risk of suicide, systematic assessment of suicide risk associated with SGA in the postmarketing setting is important and of interest to regulatory authorities. To fulfill a postmarketing request, our objective was to determine suicide event (attempted or completed) incidence in patients with schizophrenia or bipolar disorder, prescribed aripiprazole. Methods: Using administrative data from three US sources, we assessed study endpoints of suicide attempts and death by suicid e in patients aged ≥18 enrolled continuously for ≥3 months in their health plans before receiving their first ever antipsychotic (November 2002–December 2005). Results: Among 20 489 antipsychotic users (8985 patient‐years), unadjusted suicide event rates (per 1000 patient‐years) were: 20.69 (aripiprazole); 23.99 (olanzapine); 32.33 (quetiapine); 19.69 (risperidone); 48.52 (ziprasidone). Compared with current users of other SGA combined, aripiprazole users did not have an increased risk of suicide events (crude hazard ratio (HR) = 0.79, 95%CI: 0.48–1.30; adjusted HR = 0.69, 95%CI: 0.42–1.14—(controlling for study site, age, sex, index prescription year, antipsychotic use history, other pharmacotherapy exposure, comorbidity presence, schizophrenia/bipolar disorder, suicide attempts, number inpatient/outpatient encounters). Conclusions: In this large, multi‐site study, compared with other SGA combined, aripiprazole is not associated with an increased risk of suicide events in an inception cohort of patients with ICD‐9/ICD‐10 codes indicative of schizophrenia or bipolar disorder. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Suicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424
Valuck, R. J., Libby, A. M., Sills, M. R., Giese, A. A., & Allen, R. R. (2004) · CNS Drugs · doi:10.2165/00023210-200418150-00006 · Cited by 182
Cited by
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85
Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101700 · Cited by 78
Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Lai, J., Lu, Q., Zhang, P., Xu, T., Xu, Y., & Hu, S. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s122316 · Cited by 9
Metadata
- Authors
- Ulcickas Yood, M., DeLorenze, G., Quesenberry, C. P., Tsai, A., Phillips, S., Willey, V. J., Niemcryk, S. J., Wells, K., Skovron, M. L., Cziraky, M. J., Carson, W., & Oliveria, S. A.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2010-10-05
- Volume
- 19
- Issue
- 11
- Pages
- 1124-1130
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2093279255
- Cited by
- 22
- References
- 5
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.